WallStreetZenWallStreetZen

NASDAQ: AUPH
Aurinia Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their AUPH stock forecasts and price targets.

Forecast return on equity

Is AUPH forecast to generate an efficient return?

Company
31.51%
Industry
94.92%
Market
176.46%
AUPH's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AUPH forecast to generate an efficient return on assets?

Company
24.7%
Industry
27.65%
AUPH is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AUPH earnings per share forecast

What is AUPH's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$0.98-56.09%
Avg 2 year Forecast
$1.26-43.47%
Avg 3 year Forecast
$1.84-17.67%
AUPH's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

AUPH revenue forecast

What is AUPH's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$329.5M+10.47%
Avg 2 year Forecast
$391.6M+31.29%
Avg 3 year Forecast
$461.5M+54.7%
AUPH's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AUPH earnings growth forecast

How is AUPH forecast to perform vs Biotechnology companies and vs the US market?

Company
-7.34%
Industry
15.71%
Market
34.13%
AUPH's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
AUPH's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
AUPH's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

AUPH revenue growth forecast

How is AUPH forecast to perform vs Biotechnology companies and vs the US market?

Company
15.51%
Industry
33.97%
Market
13.92%
AUPH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AUPH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AUPH vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AUPH$16.14N/AN/A
MLYS$25.13$51.50+104.93%Strong Buy
NKTR$60.92$156.00+156.07%Strong Buy
IMNM$18.53$34.71+87.34%Strong Buy
BHVN$13.62$19.40+42.44%Strong Buy
View Top Biotech Stocks

Aurinia Pharmaceuticals Stock Forecast FAQ

What is AUPH's earnings growth forecast for 2026-2028?

(NASDAQ: AUPH) Aurinia Pharmaceuticals's forecast annual earnings growth rate of -7.34% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.13%.

Aurinia Pharmaceuticals's earnings in 2026 is $298,213,000.On average, 8 Wall Street analysts forecast AUPH's earnings for 2026 to be $125,926,756, with the lowest AUPH earnings forecast at $109,645,785, and the highest AUPH earnings forecast at $140,433,025. On average, 8 Wall Street analysts forecast AUPH's earnings for 2027 to be $162,128,127, with the lowest AUPH earnings forecast at $95,782,525, and the highest AUPH earnings forecast at $243,057,158.

In 2028, AUPH is forecast to generate $236,112,668 in earnings, with the lowest earnings forecast at $157,537,047 and the highest earnings forecast at $317,324,623.

If you're new to stock investing, here's how to buy Aurinia Pharmaceuticals stock.

What is AUPH's revenue growth forecast for 2026-2028?

(NASDAQ: AUPH) Aurinia Pharmaceuticals's forecast annual revenue growth rate of 15.51% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.97%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.92%.

Aurinia Pharmaceuticals's revenue in 2026 is $298,295,000.On average, 9 Wall Street analysts forecast AUPH's revenue for 2026 to be $42,378,108,645, with the lowest AUPH revenue forecast at $40,329,484,026, and the highest AUPH revenue forecast at $43,885,320,229. On average, 9 Wall Street analysts forecast AUPH's revenue for 2027 to be $50,365,558,430, with the lowest AUPH revenue forecast at $45,370,669,529, and the highest AUPH revenue forecast at $61,764,810,548.

In 2028, AUPH is forecast to generate $59,344,527,100 in revenue, with the lowest revenue forecast at $49,781,706,844 and the highest revenue forecast at $75,921,282,492.

What is AUPH's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: AUPH) forecast ROA is 24.7%, which is lower than the forecast US Biotechnology industry average of 27.65%.

What is AUPH's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: AUPH) Aurinia Pharmaceuticals's current Earnings Per Share (EPS) is $2.23. On average, analysts forecast that AUPH's EPS will be $0.98 for 2026, with the lowest EPS forecast at $0.85, and the highest EPS forecast at $1.09. On average, analysts forecast that AUPH's EPS will be $1.26 for 2027, with the lowest EPS forecast at $0.74, and the highest EPS forecast at $1.89. In 2028, AUPH's EPS is forecast to hit $1.84 (min: $1.23, max: $2.47).

What is AUPH's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: AUPH) forecast ROE is 31.51%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.